108 related articles for article (PubMed ID: 31537582)
1. Pioglitazone, Nuclear Receptors, and Aerodigestive Prevention.
Ondrey FG
Cancer Prev Res (Phila); 2019 Oct; 12(10):641-644. PubMed ID: 31537582
[TBL] [Abstract][Full Text] [Related]
2. PPARγ-Mediated p21 Induction in Aerodigestive Preneoplastic Cell Lines.
Miller WA; Wuertz BR; Ondrey FG
Ann Otol Rhinol Laryngol; 2018 Oct; 127(10):677-686. PubMed ID: 30047791
[TBL] [Abstract][Full Text] [Related]
3. PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury.
Elshazly S; Soliman E
Toxicol Appl Pharmacol; 2019 Jan; 362():86-94. PubMed ID: 30393147
[TBL] [Abstract][Full Text] [Related]
4. Novel PPARgamma-dependent and independent effects for thiazolidinediones.
Narce M; Poisson JP
Curr Opin Lipidol; 2003 Dec; 14(6):651-2. PubMed ID: 14624145
[No Abstract] [Full Text] [Related]
5. Effects of PPAR-γ agonist, pioglitazone on brain tissues oxidative damage and learning and memory impairment in juvenile hypothyroid rats.
Baghcheghi Y; Salmani H; Beheshti F; Shafei MN; Sadeghnia HR; Soukhtanloo M; Ebrahimzadeh Bideskan A; Hosseini M
Int J Neurosci; 2019 Oct; 129(10):1024-1038. PubMed ID: 31215278
[No Abstract] [Full Text] [Related]
6. PPAR-γ agonist pioglitazone protects against IL-17 induced intervertebral disc inflammation and degeneration via suppression of NF-κB signaling pathway.
Liu Y; Qu Y; Liu L; Zhao H; Ma H; Si M; Cheng L; Nie L
Int Immunopharmacol; 2019 Jul; 72():138-147. PubMed ID: 30981079
[TBL] [Abstract][Full Text] [Related]
7. Effects of Pioglitazone on Glucose-Dependent Insulinotropic Polypeptide-Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients With Type 2 Diabetes.
Tharp WG; Gupta D; Sideleva O; Deacon CF; Holst JJ; Elahi D; Pratley RE
Diabetes; 2020 Feb; 69(2):146-157. PubMed ID: 31757794
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats.
Grešová L; Kvandova M; Kvasnicka P; Dovinova I
Gen Physiol Biophys; 2019 May; 38(3):259-264. PubMed ID: 31184312
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Neuroinflammatory Signaling by PPARγ Agonist in Mouse Model of Diabetes.
Piątkowska-Chmiel I; Herbet M; Gawrońska-Grzywacz M; Dudka J
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628311
[TBL] [Abstract][Full Text] [Related]
10. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.
Joardar A; Menzl J; Podolsky TC; Manzo E; Estes PS; Ashford S; Zarnescu DC
Hum Mol Genet; 2015 Mar; 24(6):1741-54. PubMed ID: 25432537
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.
Murakami-Nishida S; Matsumura T; Senokuchi T; Ishii N; Kinoshita H; Yamada S; Morita Y; Nishida S; Motoshima H; Kondo T; Komohara Y; Araki E
Atherosclerosis; 2019 Jul; 286():30-39. PubMed ID: 31096071
[TBL] [Abstract][Full Text] [Related]
12. PPARγ Agonist PGZ Attenuates OVA-Induced Airway Inflammation and Airway Remodeling via RGS4 Signaling in Mouse Model.
Meng X; Sun X; Zhang Y; Shi H; Deng W; Liu Y; Wang G; Fang P; Yang S
Inflammation; 2018 Dec; 41(6):2079-2089. PubMed ID: 30022363
[TBL] [Abstract][Full Text] [Related]
13. Development of chemopreventive agents for lung and upper aerodigestive tract cancers.
Kelloff GJ; Boone CW; Steele VK; Perloff M; Crowell J; Doody LA
J Cell Biochem Suppl; 1993; 17F():2-17. PubMed ID: 8412195
[TBL] [Abstract][Full Text] [Related]
14. PPAR γ agonist, pioglitazone, suppresses melanoma cancer in mice by inhibiting TLR4 signaling.
Dana N; Vaseghi G; Haghjooy Javanmard S
J Pharm Pharm Sci; 2019; 22(1):418-423. PubMed ID: 31509504
[TBL] [Abstract][Full Text] [Related]
15. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention strategies for lung and upper aerodigestive tract cancer.
Benner SE; Lippman SM; Hong WK
Cancer Res; 1992 May; 52(9 Suppl):2758s-2763s. PubMed ID: 1563008
[TBL] [Abstract][Full Text] [Related]
17. Reverting Metabolic Dysfunction in Cortex and Cerebellum of APP/PS1 Mice, a Model for Alzheimer's Disease by Pioglitazone, a Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Agonist.
Chang KL; Wong LR; Pee HN; Yang S; Ho PC
Mol Neurobiol; 2019 Nov; 56(11):7267-7283. PubMed ID: 31016475
[TBL] [Abstract][Full Text] [Related]
18. A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress.
Mirza R; Sharma B
Chem Biol Interact; 2019 Sep; 311():108758. PubMed ID: 31348919
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
20. Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Pharmacol Sci; 2019 Jan; 139(1):46-49. PubMed ID: 30522964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
